1) Neurodegenerative disorders
2) Immunotherapy Gene delivery
3) Adeno associated virus,
4) recombinant antibodies
5) Alzheimer & Parkinsons disease
6) Amyloid
7) Protein aggregation

1. Kim JY,Grunke, SD, Levites, Y, Golde, TE, Jankowsky, JJ. Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction, JoVE, 2014, in press.
2. Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, Ran Y, Golde TE, Giasson BI. Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein. ActaNeuropatholCommun. 2013 Jul 17;1(1):38.
3. Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Jansen K, Borchelt DR, Kim JY, Jankowsky J, Golde TE, Levites Y. Capsid Serotype and Timing of Injection determines AAV transduction in the Neonatal Mice Brain. PLOS One, ;8(6):e67680.
4. Clippinger AK, D\'Alton S, Lin WL, Gendron TF, Howard J, Borchelt DR, Cannon A, Carlomagno Y, Chakrabarty P, Cook C, Golde TE, Levites Y, Ranum L, Schultheis PJ, Xu G, Petrucelli L, Sahara N, Dickson DW, Giasson B, Lewis J. Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.ActaNeuropathol. 2013 May 11
5. Kim JY, Ash RT, Ceballos-Diaz C, Levites Y, Golde TE, Smirnakis SM, Jankowsky JL. Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo.Eur J Neurosci. 2013 Apr;37(8):1203-20. Epub 2013 Jan 24.
6. Aβ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC, Levites Y, Edwards SR, Golde TE, Hyman BT, Barnea G, Albers MW. Nat Commun. 2012;3:1009. doi: 10.1038/ncomms2013.
7. Overlapping profiles of Aβ peptides in the Alzheimer\'s disease and pathological aging brains. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE. Alzheimers Res Ther. 2012 May 23;4(3):18.
8. Shanta Boddapati, BS; Yona Levites, PhD; Michael R Sierks. Inhibiting -secretase activity in Alzheimer\'s disease cell models with single chain antibodiesspecifically targeting APP. Journal of Molecular Biology, in press.
9. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y,Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses A{beta} deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2009 Oct 14. [Epub ahead of print]
10. Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, Federoff HJ, Bowers WJ. Generating Differentially Targeted Amyloid-beta Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer\'s DiseaseMolTher. 2009 Jul 28. [Epub ahead of print].
11. Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of abeta immunotherapy.CNS NeurolDisord Drug Targets.2009; ;8(1):31-49.
12. Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K, Rangachari V, Zou F, Younkin SG, Graff-Radford N, Dickson D, Rosenberry T, Golde TE. BRI2 (ITM2b) inhibits Abeta deposition in vivo. J Neurosci. 2008 ; 28(23):6030-6.
13. Laifenfeld D, Patzek LJ, McPhie DL, Chen Y, Levites Y,Cataldo AM, Neve RL. Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. J Neurosci. 2007 Jul 4;27(27):7141-53.
14. Levites Y, Das P, Smithson L, Golde T. Anti-A Antibodies Work at SubstochiometricLevles to Alter APP Transgenic Mice, FASEB Journal,2006 Dec;20(14):2576-8.
15. Levites Y.; Jansen K.; Smithson L; Holloway V.M.; Das P.;Golde T.E., Intracranial AAV mediated delivery of anti-pan A, A40 and A42 scFvs attenuates plaque pathology in APP mice, J. Neurosci., 2006; 26(46):11923-8.